147267-15-0

Basic information

• Product Name: (2S,4R)-BOC-4-PHENOXY-PYRROLIDINE-2-CARBOXYLIC ACID
• Synonyms: (2S,4R)-BOC-4-PHENOXY-PYRROLIDINE-2-CARBOXYLIC ACID;(2S,4R)-BOC-4-PHENOXY-PYRROLIDACID;(4R)-1-Boc-4-phenoxy-L-proline;(2S,4R)-Boc-4-phenoxy-Pro-OH;(2S,4R)-1-(tert-butoxycarbonyl)-4-phenoxypyrrolidine-2-carboxylic acid
• CAS NO: 147267-15-0
• Molecular Formula: C16H21NO5
• Molecular Weight: 307.34
• Mol File: 147267-15-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S,4R)-BOC-4-PHENOXY-PYRROLIDINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-BOC-4-PHENOXY-PYRROLIDINE-2-CARBOXYLIC ACID(147267-15-0)
• EPA Substance Registry System: (2S,4R)-BOC-4-PHENOXY-PYRROLIDINE-2-CARBOXYLIC ACID(147267-15-0)

Safety Data

• Hazardous Substances Data: 147267-15-0(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 221050-87-9 N-Boc-cis-4-phenoxy-L-proline benzyl ester 
• 108-95-2 phenol 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 93967-75-0 methyl (1-tert-butoxycarbonyl)-(4S)-phenoxy-(2S)-pyrrolidinylcarboxylate 

Downstream Products

• 317357-20-3 (2S,4S)-1-tert-butoxycarbonyl-4-phenoxy-2-pyrrolidine carbaldehyde 

Relevant articles and documents

MASP-2 INHIBITORS AND METHODS OF USE

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

Rationally designed 4-phenoxy substituted prolinamide phenols organocatalyst for the direct aldol reaction in water

A rationally designed 4-phenoxy substituted prolinamide phenols as an efficient hydrophobic organocatalyst for direct asymmetric aldol reaction in water has been developed. High yield (up to 99%), diastereoselectivity (up to 99:1), and enantioselectivity (up to 97%) were obtained under optimal condition. The influence of substituent groups on the reactivity of catalysts was studied in detail. Crown Copyright

Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

A series of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives were synthesized and evaluated for their activity as VLA-4 antagonists. Of 22 compounds synthesized, 19 compounds showed potent activity with low nanomolar IC50 values. In addition, the representative compounds 11o and 11p with a hydroxy group in the pyrrolidine ring showed moderate plasma clearance in rats (11o, 30 ml/min/kg and 11p, 21 ml/min/kg) and in dogs (11o, 12 ml/min/kg and 11p, 9 ml/min/kg).

NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES

The present invention relates to compounds with the formulas (I), (II), and (III), or a pharmaceutically acceptable salt thereof: wherein T is a (4 to 10)-membered heterocyclyl selected from the group consisting of and wherein R1. R2 and R3 are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formulas (I), (II), and (III) and methods of treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme, the method comprising administering to a mammal an effective amount of a compound of formulas (I), (II), and (III).

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.